The right outcome begins with the right test

Trust the rapid, digitally displayed results of the BD Veritor™ Plus System to guide your patients to the appropriate path to care

BD

The reliable point-of-care testing of the BD Veritor™ Plus System brings more clarity.

As more patients are seeking answers and treatment in their communities, accessible point-of-care testing is more critical than ever. Testing can help differentiate between and diagnose respiratory tract infections (RTIs), potentially leading to treatments that can help minimize spread as well as disease duration and severity.[1-4]

Rapid diagnostics provide further confidence that your patients are on the appropriate path to care

Trust BD for the digital difference

The BD Veritor™ Plus System offers a point-of-care testing solution to deliver unambiguous, digitally read results for SARS-CoV-2*, SARS-CoV-2 & Flu A+B, Group A Strep, and RSV. It offers:**

- An easy-to-use device—the BD Veritor™ Plus Analyzer—that simplifies implementation and presents rapid, reliable results digitally
- A range of assays to identify the relevant path to care for symptomatic patients so they can take their next steps with more confidence



Results in	15 mins[4]	15 mins[5]	10 mins[6]	10 mins[7]	5 mins[8]

Reliable results in a timely manner allow you to quickly diagnose and improve care for your patients[2,3]

RSV=respiratory syncytial virus; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.

*Under an Emergency Use Authorization (EUA) from the FDA. Refer to the back cover.

Choose the digital testing solution of the BD Veritor™ Plus System for your patients and community

Unambiguous, **easy-to-read results** displayed on a digital screen

The Analyzer can deliver RTI results (depending on the assay) **in 15 minutes or less** for increased efficiency

A portable instrument, small enough to fit in a person's hand

Maintenance-free and calibration-free instrumentation

Operational flexibility to meet your team's workflow needs

Seamless results management and reporting via optional **connectivity solutions**

Single-button functionality to easily switch between operating modes

A rechargeable battery for continuous testing

Simplified staff training and ongoing support with comprehensive **training resources**

The BD Veritor™ Plus Analyzer fits easily into your practice's point-of-care testing workflow

Combine easy sample collection and testing workflows for reliable answers you can use

The BD Veritor™ Plus System offers operational flexibility, with 2 modes designed to meet your workflow needs.



Analyze Now Mode

Batch* multiple tests simultaneously (default mode)

OR

Walk Away Mode

Plug in and the device will time the test (2 clicks away)

The BD Veritor™ Plus System also provides an easy sample-collection process that can be incorporated across a variety of clinical settings.

Step 1

Collect sample**

Step 2

Mix the swab with the reagent vial

Step 3

Prepare assay with the sample

Step 4

Run the test

Step 5



Insert the cartridge and read the results

*Batch testing refers to Triplex and SARS-CoV-2 standalone tests only.

**For Group A Strep, add 3 drops of Reagent 1 to the Reagent 2 vial and inoculate the sample for 1 to 2 minutes prior to assay preparation.

Test. Connect. Report.

The BD Veritor™ Plus System helps you and your team manage and report test results with multiple connectivity capabilities to fit your practice's needs.

BD Veritor™ InfoWiFi Module

A barcode scanner that captures and links additional information with each result.

ImageMover

A smartphone app that offers results management and notification services.



BD Synapsys™ Informatics

An integrated informatics solution that enables secure, seamless access and real-time connectivity to BD instruments.

Capability	Analyzer	Analyzer* + InfoWiFi*	Analyzer* + ImageMover*	Analyzer* + InfoWiFi* + ImageMover*	Analyzer* + InfoWiFi* + BD Synapsys™*
Rapid, digital results	✓	✓	✓	✓	✓
Identifiable results†		✓	✓	✓	✓
Downloadable results		✓	✓	✓	✓
Automatic patient notification			✓	✓	✓
Public health reporting			✓	✓	✓
Automatic real-time results transmission				✓	✓
Integration with EMR/LIS					✓
Live instrumentation status monitoring					✓

Together we can customize an effective and connected reporting solution for your practice.

EMR=electronic medical records; LIS=laboratory information systems.

*Requires a barcoded workflow.

†Test result is associated with Patient ID, Operator ID, and Kit Lot information.

How to order the BD Veritor™ Plus System

Contact your distributor today. Not sure who to contact? We are here to help!
Reach out to us at VeritorCares@bd.com or call 1-800-638-8663.

BD Product No.	Product Description	Quantity
256066	BD Veritor™ Plus Analyzer	1 unit
256088	BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B	30 tests
256082	BD Veritor™ System for Rapid Detection of SARS-CoV-2	30 tests
256045	BD Veritor™ System for Rapid Detection of Flu A+B	30 tests
256041	BD Veritor™ System for Rapid Detection of Flu A+B (moderately complex)	30 tests
256038	BD Veritor™ System for Rapid Detection of RSV	30 tests
256042	BD Veritor™ System for Rapid Detection of RSV (moderately complex)	30 tests
256040	BD Veritor™ System for Rapid Detection of Group A Strep	30 tests
445010	BD Veritor™ InfoWiFi Module	1 unit
443907	USB Printer Cable	1 unit

Test kits are CLIA-waived unless stated moderately complex.

Click **here** to view the clinical performance of the BD Veritor™ Plus System.

Together we can help protect the health and wellness of patients and their communities

References: 1. Centers for Disease Control and Prevention. Treatments your healthcare provider might recommend if you are sick. Updated January 13, 2022. Accessed March 18, 2022. https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html **2.** Huang G, Gong T, Wang G, et al. Timely diagnosis and treatment shortens the time to resolution of coronavirus disease (COVID-19) pneumonia and lowers the highest and last CT scores from sequential chest CT. *AJR Am J Roentgenol.* 2020;215(2):367-373. **3.** Koonin LM, Patel A. Timely antiviral administration during an influenza pandemic: key components. *Am J Public Health.* 2018;108(Suppl 3):S215-S220. **4.** BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B. Package insert, 500051910. Becton, Dickinson and Company. **5.** BD Veritor™ System for Rapid Detection of SARS-CoV-2. Package insert, 500048916. Becton, Dickinson and Company. **6.** BD Veritor™ System for Rapid Detection of Flu A+B. Package insert, 8087667. Becton, Dickinson and Company. **7.** BD Veritor™ System for Rapid Detection of Respiratory Syncytial Virus (RSV). Package insert, 8086098. Becton, Dickinson and Company. **8.** BD Veritor™ System for Rapid Detection of Group A Strep. Package insert, 8087675. Becton, Dickinson and Company.

The BD Veritor™ Plus System

Training solutions tailored to support your team and instill confidence

BD offers support and resources based on your team's needs so you and your team feel confident using the BD Veritor™ Plus System.

Whether you are a first-time user or a seasoned veteran, BD provides a variety of learning options to help you and your team confidently administer trusted, reliable point-of-care testing with the BD Veritor™ Plus System.

Click to access training modules on the BD Veritor™ YouTube channel

Contact us to request a demo

Learn more at bdveritor.com

*In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 this product has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID 19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

**In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID 19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

BD